Specialty Pharmacy

Glecaprevir/pibrentasvir found to be effective in clinical trials treating patients with hepatitis C virus also being treated for opioid substitution therapy.

Specialty medications are still mostly branded products, but patients remain hesitant to accept less expensive generic alternatives when the option is available.

The study points to the importance of screening for and treating arthritis-related pain in older adults with varying degrees of depression.

Top news of the day from across the health care landscape.

Millennials, Generation X, and Baby Boomers all have different health care needs.

Siponimod is an oral, once-daily medication for the treatment of multiple sclerosis in adults.

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the emergence of CAR T-cell therapy as a groundbreaking oncology treatment.

Inotersen (Tegsedi) once-weekly subcutaneous injection is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Survey data reveal rates of diabetes prevalence by subtype among adults.

Top news of the day from across the health care landscape.

Officials with the National Community Pharmacists Association called the opioid relief package that is awaiting President Trump's signature "vital."

Clinical trial data show results from switching to Delstrigo from other antiretroviral treatments for HIV.

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference, Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discussed several pieces of legislation in Congress that could impact specialty pharmacy.

Top news of the day from across the health care landscape.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Emicizumab-kxwh (Hemlibra) is now the only FDA-approved treatment for hemophilia A with and without factor VIII inhibitors.

A combination of 2 anti-HIV antibodies may be capable of suppressing HIV for months after treatment.

Artificial intelligence tool can analyze images of patients’ lung tumors, specify cancer types, and identify altered genes driving abnormal cell growth.

Top news of the day from across the health care landscape.

The increased risk of cancer is due in part to people living with HIV living longer, thanks to advances like antiretroviral therapy.

FDA officials have approved omadacycline (Nuzyra, Paratek), a modernized tetracycline, to treat adults with acute skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Study examines the role of liver macrophages as a long-lived HIV-1 cellular reservoir.

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference, Mike Agostino, RPh, President of NASP, discussed how the organization advocates for the profession.

Top news of the day from across the health care landscape.

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

Epidiolex was approved to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—in patients aged 2 years and older.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the day from across the health care landscape.